Loading
Liver Disease Diagnosis and Treatment · Journal article
Frontiers in Endocrinology · August 7, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of mechanisms linking gut microbiota, obesity, and natural medicines. The authors synthesize preclinical evidence showing that natural medicines can reshape the microbiota through increased SCFAs, barrier enhancement, and gut–brain axis modulation, but explicitly acknowledge that well-controlled human trials remain sparse and causal relationships are not yet established.
Narrative review. Obese individuals and those at risk of type 2 diabetes mellitus, cardiovascular diseases, and metabolic dysfunction-associated steatotic liver disease.
Obesity affects more than 1.5 billion people worldwide and increases risk of T2DM, cardiovascular disease, and MASLD In obesity, gut microbial diversity often declines with increased Firmicutes/Bacteroidetes ratio, disrupting energy homeostasis and promoting lipid accumulation Natural medicines including phytochemicals, herbal extracts, and multi-herb formulas can mitigate obesity by reshaping the microbiota
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review provides mechanistic rationale for investigating natural medicines as obesity therapies through microbiota modulation, but readers should note that human evidence is currently limited and causal links between specific microbiota changes and obesity outcomes remain to be established. Clinical application is not yet supported by well-controlled human trials.
A narrative review synthesizing preclinical evidence and mechanistic pathways; acknowledges that human trials are limited and causal links are not yet established, making this exploratory rather than confirmatory.
As stated by the source record.
Quoted from the source exactly as published.
This review provides mechanistic rationale for investigating natural medicines as obesity therapies through microbiota modulation, but readers should note that human evidence is currently limited and causal links between specific microbiota changes and obesity outcomes remain to be established. Clinical application is not yet supported by well-controlled human trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Obesity has become a major global public health challenge, affecting more than 1.5 billion people worldwide and markedly increasing the risk of chronic diseases, including type 2 diabetes mellitus (T2DM), cardiovascular diseases, and metabolic dysfunction-associated steatotic liver disease (MASLD). In recent years, the gut microbiota has emerged as a critical regulator of host metabolism, immune homeostasis, and energy balance and has been increasingly implicated in the development and pathogenesis of obesity. In obesity, gut microbial diversity often declines and community composition shifts (e.g., increased Firmicutes/Bacteroidetes ratio), which can disrupt energy homeostasis, promote lipid accumulation, trigger chronic inflammation, and alter appetite regulation. This review highlights evidence that natural medicines – including purified phytochemicals, standardized herbal extracts, and traditional multi-herb formulas – can mitigate obesity by beneficially reshaping the gut microbiota. Key mechanisms identified include restoration of microbial balance, increased production of short-chain fatty acids (SCFAs), enhancement of intestinal barrier integrity, and modulation of the gut–brain axis. However, most current evidence derives from preclinical studies; well-controlled human trials of microbiota-targeted natural therapies are still limited, and causal links between specific microbiota shifts and obesity outcomes remain to be established. Collectively, these findings provide a rationale for developing microbiota-oriented natural therapeutic strategies for obesity.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.